ArticleFrontiers in medicine2025
Elevated triglyceride-glucose index increases risk in patients with retinal vein occlusion.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Retinal vein occlusion (RVO) is the second most prevalent retinal vascular disorder, and persistent macular edema secondary to RVO is a leading cause of visual impairment. Emerging studies have indicated that the triglyceride-glucose (TyG) index holds clinical significance in assessing vascular damage. This study aimed to investigate the role of the TyG index in patients with RVO. Methods: In this retrospective study, we examined 51 patients diagnosed with RVO alongside 54 age- and sex-matched control subjects. Comprehensive ocular examinations were performed, and various hematological parameters, including fasting blood glucose, total cholesterol, triglycerides, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol, were obtained through blood biochemistry tests. The TyG index was calculated using fasting plasma glucose and triglyceride levels. A logistic regression analysis was used to assess the association between these lipid markers and the risk of RVO. The receiver operating characteristic (ROC) curve was used to evaluate the predictive values of the TyG index in relation to RVO. Data analysis was conducted using IBM SPSS Statistics (Version 22), with statistical significance set at a Results: Among the hematological parameters assessed, no statistically significant differences were observed between the two groups regarding glucose, total cholesterol, and low-density lipoprotein cholesterol (LDL-C) ( Conclusion: Our findings indicate that the TyG index is elevated in patients diagnosed with retinal vein occlusion. Therefore, the TyG index may serve as a significant predictive biomarker for identifying individuals at risk of developing retinal vein occlusion.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.